<DOC>
	<DOCNO>NCT00964665</DOCNO>
	<brief_summary>This study ass efficacy ABF656 chronic hepatitis B characterize HBeAg positivity . The study design establish dose response safety relationship sufficient allow subsequent design conduct Phase 3 trial . The trial also design generate PK data hepatitis B patient satisfy regulatory requirement China .</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Albinterferon Alfa-2b Chronic Hepatitis B , eAg+ , Infection Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female , age 1875 year either nonchild bearing potential child bear potential two adequate form birth control Chronic HBV infection ( serum HBsAg detectable &gt; 6 month ) Serum HBeAg positive HBV DNA &gt; 106copies/mL ( &gt; 200,000 IU/mL ) Serum ALT must &gt; 2 x ULN 10 x ULN Steroid treatment immunosuppression 3 month prior entry . Chest Xray clinically significant active inflammatory process , history significant pulmonary disease history interstitial lung disease . Hb &lt; 10g/dL , ANC &lt; 750/mm3 , platelet count &lt; 75,000 mm3 . Significant chronic medical condition chronic hepatitis B opinion investigator preclude enrollment study . Evidence hepatic decompensation ( i.e. , ChildPugh score B C ) . Seropositive HIV , HCV , HDV ( Hepatitis Delta virus ) . History hypothyroidism current treatment thyroid disease . Patients treat untreated malignancy organ , exception localize basal cell carcinoma Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Hepatitis B ,</keyword>
	<keyword>Chronic ,</keyword>
	<keyword>Hepatitis B e Antigens positive</keyword>
</DOC>